A Study of Suboptimally Controlled Participants Previously Taking Oral or Infusion DMDs for RMS (MASTER-2)
- First Posted Date
- 2019-05-01
- Last Posted Date
- 2025-04-06
- Target Recruit Count
- 291
- Registration Number
- NCT03933202
- Locations
- 🇺🇸
Northwest Houston Neurology, Cypress, Texas, United States
🇺🇸VCU Medical Center - Pediatric Neurology, Richmond, Virginia, United States
🇺🇸Sentara Ambulatory Care Center, Virginia Beach, Virginia, United States
M7824 in Combination With Chemotherapy in Stage IV Non-small Cell Lung Cancer (NSCLC)
- Conditions
- Carcinoma, Non-Small-Cell Lung
- Interventions
- First Posted Date
- 2019-02-15
- Last Posted Date
- 2023-08-21
- Target Recruit Count
- 70
- Registration Number
- NCT03840915
- Locations
- 🇺🇸
Compassionate Care Research Group Inc - Edinger Medical Group, Inc., Fountain Valley, California, United States
🇺🇸RCCA MD LLC - Bethesda, Bethesda, Maryland, United States
🇺🇸University of Maryland - DUPLICATE/Pediatric Surgery, Baltimore, Maryland, United States
M7824 With cCRT in Unresectable Stage III Non-small Cell Lung Cancer (NSCLC)
- Conditions
- Non-small Cell Lung Cancer
- Interventions
- Drug: PlaceboRadiation: Intensity Modulated Radiation Therapy (IMRT)
- First Posted Date
- 2019-02-15
- Last Posted Date
- 2024-01-16
- Target Recruit Count
- 153
- Registration Number
- NCT03840902
- Locations
- 🇺🇸
University of Texas MD Anderson Cancer Center - Unit 432 Thoracic Head and Neck Medical Oncology, Houston, Texas, United States
🇺🇸Lynn Cancer Institute Center, Boca Raton, Florida, United States
🇺🇸American Health Network of Indiana, LLC, Indianapolis, Indiana, United States
M7824 Monotherapy in Locally Advanced or Metastatic Second Line (2L) Biliary Tract Cancer (Cholangiocarcinoma and Gallbladder Cancer)
- Conditions
- CholangiocarcinomaGallbladder CancerBiliary Tract Cancer
- Interventions
- First Posted Date
- 2019-02-07
- Last Posted Date
- 2023-10-25
- Target Recruit Count
- 159
- Registration Number
- NCT03833661
- Locations
- 🇺🇸
MD Anderson Cancer Center - Unit, Houston, Texas, United States
🇯🇵Kindai University Hospital - Dept of Gastroenterology, Osakasayama-shi, Japan
🇪🇸Hospital de la Santa Creu i Sant Pau, Barcelona, Spain
Avelumab Program Rollover Study
- First Posted Date
- 2019-01-24
- Last Posted Date
- 2025-05-14
- Target Recruit Count
- 205
- Registration Number
- NCT03815643
- Locations
- 🇺🇸
Norwalk Hospital - The Whittingham Cancer Center, Norwalk, Connecticut, United States
🇺🇸HonorHealth Research Institute, Scottsdale, Arizona, United States
🇺🇸Highlands Oncology Group, Fayetteville, Arkansas, United States
Study of Peposertib in Combination With Capecitabine and RT in Rectal Cancer
- Conditions
- Locally Advanced Rectal Cancer
- Interventions
- Drug: Peposertib 100 mgDrug: Peposertib 250 mgDrug: Peposertib 150 mgDrug: Peposertib 50 mgRadiation: Radiotherapy (RT)
- First Posted Date
- 2018-12-10
- Last Posted Date
- 2023-03-21
- Target Recruit Count
- 19
- Registration Number
- NCT03770689
- Locations
- 🇺🇸
Ohio State University Clinical Trials Management Office - Ohio State CTMO Parent, Columbus, Ohio, United States
🇺🇸University of Colorado Cancer Center, Aurora, Colorado, United States
🇺🇸Northwell Health, Inc, Great Neck, New York, United States
Study of Avelumab-M3814 Combinations
- Conditions
- OncologySolid Tumors
- Interventions
- First Posted Date
- 2018-10-30
- Last Posted Date
- 2025-04-10
- Target Recruit Count
- 57
- Registration Number
- NCT03724890
- Locations
- 🇺🇸
H. Lee Moffitt Cancer Center and Research Institute, Inc, Tampa, Florida, United States
🇺🇸The University of Chicago Medical Center, Chicago, Illinois, United States
🇺🇸Mount Sinai - PRIME (10707), Lake Success, New York, United States
Phase Ib/II Study of Carboplatin + M6620 + Avelumab in PARPi-resistant Ovarian Cancer
- First Posted Date
- 2018-10-12
- Last Posted Date
- 2020-11-13
- Target Recruit Count
- 3
- Registration Number
- NCT03704467
- Locations
- 🇺🇸
The Stamford Hospital, Stamford, Connecticut, United States
🇺🇸Marin Cancer Care, Inc., Greenbrae, California, United States
🇺🇸Covenant Health Care, Saginaw, Michigan, United States
M7824 Versus Pembrolizumab as a First-line (1L) Treatment in Participants With Programmed Death-ligand 1 (PD-L1) Expressing Advanced Non-small Cell Lung Cancer (NSCLC)
- First Posted Date
- 2018-08-15
- Last Posted Date
- 2025-04-08
- Target Recruit Count
- 304
- Registration Number
- NCT03631706
- Locations
- 🇺🇸
Cedars Sinai Medical Center - Inflammatory Bowel Disease Center (Clinic, Los Angeles, California, United States
🇺🇸Decatur Memorial Hospital - Clinical Research, Decatur, Illinois, United States
🇺🇸UPMC Cancer Center, Pittsburgh, Pennsylvania, United States
Tepotinib Hepatic Impairment Trial
- First Posted Date
- 2018-06-06
- Last Posted Date
- 2024-08-12
- Target Recruit Count
- 18
- Registration Number
- NCT03546608
- Locations
- 🇺🇸
Qps Mra, Llc, Miami, Florida, United States
🇺🇸Orlando Clinical Research Center, Orlando, Florida, United States